Literature DB >> 1868880

Effects and aftereffects of ibogaine on morphine self-administration in rats.

S D Glick1, K Rossman, S Steindorf, I M Maisonneuve, J N Carlson.   

Abstract

Ibogaine, a naturally occurring alkaloid, has been claimed to be effective in treating addition to opiate and stimulant drugs. As a preclinical test of this claim, the present study sought to determine if ibogaine would reduce the intravenous self-administration of morphine in rats. Ibogaine dose dependently (2.5-80 mg/kg) decreased morphine intake in the hour after ibogaine treatment (acute effect) and, to a lesser extent, a day later (aftereffect); while the acute effect could be attributed to abnormal motor behavior (whole body tremors), the aftereffect occurred at a time when ibogaine should have been entirely eliminated from the body and when there was no obvious indication of ibogaine exposure. In some rats, there was a persistent decrease in morphine intake for several days or weeks after a single injection of ibogaine; other rats began to show such persistent changes only after two or three weekly injections whereas a few rats were apparently resistant to prolonged aftereffects. Aftereffects could not be attributed to a conditioned aversion. Although ibogaine also depressed responding acutely in rats trained to bar-press for water, there was no evidence of any aftereffect a day or more later; the interaction between ibogaine and morphine reinforcement was therefore somewhat specific. Further studies are needed to characterize the nature of the ibogaine-morphine interaction as well as to determine if ibogaine also affects the self-administration of other drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868880     DOI: 10.1016/0014-2999(91)90474-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

1.  Neuropharmacological characterization of local ibogaine effects on dopamine release.

Authors:  M S Reid; K Hsu; K H Souza; P A Broderick; S P Berger
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Plants with Anti-Addictive Potential.

Authors:  Eduardo Luis Konrath; Marcelo Dutra Arbo; Bruno Dutra Arbo; Mariana Appel Hort; Elaine Elisabetsky; Mirna Bainy Leal
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

4.  Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Authors:  J K Staley; Q Ouyang; J Pablo; W L Hearn; D D Flynn; R B Rothman; K C Rice; D C Mash
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

5.  Long-lasting ibogaine protection against NMDA-induced convulsions in mice.

Authors:  M B Leal; D O de Souza; E Elisabetsky
Journal:  Neurochem Res       Date:  2000-08       Impact factor: 3.996

6.  Pharmacological comparison of the effect of ibogaine and 18-methoxycoronaridine on isolated smooth muscle from the rat and guinea-pig.

Authors:  M K Mundey; N A Blaylock; R Mason; S D Glick; I M Maisonneuve; V G Wilson
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

7.  Neurochemical and behavioural interactions between ibogaine and nicotine in the rat.

Authors:  M E Benwell; P E Holtom; R J Moran; D J Balfour
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

8.  Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Authors:  Laurie Cloutier-Gill; Evan Wood; Trevor Millar; Caroline Ferris; M Eugenia Socias
Journal:  J Psychoactive Drugs       Date:  2016-05-18

Review 9.  Ibogaine-associated cardiac arrest and death: case report and review of the literature.

Authors:  Jessica A Meisner; Susan R Wilcox; Jeremy B Richards
Journal:  Ther Adv Psychopharmacol       Date:  2016-01-13

10.  Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum.

Authors:  L G Harsing; H Sershen; A Lajtha
Journal:  J Neural Transm Gen Sect       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.